333 related articles for article (PubMed ID: 19292590)
1. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.
Campo RE; Da Silva BA; Cotte L; Gathe JC; Gazzard B; Hicks CB; Klein CE; Chiu YL; King MS; Bernstein BM
AIDS Res Hum Retroviruses; 2009 Mar; 25(3):269-75. PubMed ID: 19292590
[TBL] [Abstract][Full Text] [Related]
2. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
[TBL] [Abstract][Full Text] [Related]
3. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
4. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
King MS; Bernstein BM; Walmsley SL; Sherer R; Feinberg J; Sanne I; Cernohous P; Montaner JS; Brun SC; Sun E
J Infect Dis; 2004 Jul; 190(2):280-4. PubMed ID: 15216462
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
6. Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
Moltó J; Santos JR; Negredo E; Miranda C; Videla S; Clotet B
J Antimicrob Chemother; 2007 Aug; 60(2):436-9. PubMed ID: 17556354
[TBL] [Abstract][Full Text] [Related]
7. Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study).
Nunes EP; Santini de Oliveira M; Merçon M; Zajdenverg R; Faulhaber JC; Pilotto JH; Ribeiro JE; Norton M; Schechter M
HIV Clin Trials; 2009; 10(6):368-74. PubMed ID: 20133267
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K
J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375
[TBL] [Abstract][Full Text] [Related]
9. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
Ghosn J; Chaix ML; Peytavin G; Bresson JL; Galimand J; Girard PM; Raffi F; Cohen-Codar I; Delfraissy JF; Rouzioux C
J Antimicrob Chemother; 2008 Jun; 61(6):1344-7. PubMed ID: 18343806
[TBL] [Abstract][Full Text] [Related]
10. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.
De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M
Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
[TBL] [Abstract][Full Text] [Related]
12. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M;
AIDS; 2008 Jan; 22(2):F1-9. PubMed ID: 18097218
[TBL] [Abstract][Full Text] [Related]
13. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.
Molina JM; Podsadecki TJ; Johnson MA; Wilkin A; Domingo P; Myers R; Hairrell JM; Rode RA; King MS; Hanna GJ
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1505-14. PubMed ID: 18160008
[TBL] [Abstract][Full Text] [Related]
14. Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy.
Tran TA; Ghosn J; Avettand-Fenoël V; Hendel-Chavez H; de Goër de Herve MG; Cohen-Codar I; Rouzioux C; Delfraissy JF; Taoufik Y
J Antimicrob Chemother; 2015 Sep; 70(9):2627-31. PubMed ID: 26023212
[TBL] [Abstract][Full Text] [Related]
15. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.
Cameron DW; da Silva BA; Arribas JR; Myers RA; Bellos NC; Gilmore N; King MS; Bernstein BM; Brun SC; Hanna GJ
J Infect Dis; 2008 Jul; 198(2):234-40. PubMed ID: 18540803
[TBL] [Abstract][Full Text] [Related]
16. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
17. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%.
Shuter J; Sarlo JA; Kanmaz TJ; Rode RA; Zingman BS
J Acquir Immune Defic Syndr; 2007 May; 45(1):4-8. PubMed ID: 17460469
[TBL] [Abstract][Full Text] [Related]
18. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
Bunupuradah T; Bowonwattanuwong C; Jirajariyavej S; Munsakul W; Klinbuayaem V; Sophonphan J; Mahanontharit A; Hirschel B; Ruxrungtham K; Ananworanich J;
Antivir Ther; 2014; 19(6):579-86. PubMed ID: 24464590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]